comparemela.com

Latest Breaking News On - Kintor pharma - Page 6 : comparemela.com

Kintor Pharma Announced the Primary Endpoint of Phase II Clinical Study for KX-826 s Treatment of Female Androgenetic Alopecia in China Was Met

/PRNewswire/ Kintor Pharmaceutical Limited ("KintorPharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and.

Kintor pharmaJianzhong zhangKintor pharmaceutical limited kintorpharmaDepartment of dermatologyUniversity people hospitalKintor pharmaceutical limitedPeking university peopleSavin scaleYouzhi tongChief executive officer

Kintor Pharma announced completion of phase I trial of the world s first PROTAC compound (GT20029) for topical use

DJ Kintor Pharma announced completion of phase I trial of the world's first PROTAC compound (GT20029) for topical use EQS Newswire / 24/11/2022 / 09:48 UTC+8 Kintor Pharma announced completion

Kintor pharmaChina national medical products administrationDrug administrationFinancial pressKintor pharmaceuticalKintor pharmaceutical limited pharmaPharmaceutical limitedProteolysis targeting chimeraYouzhi tongChief executive officerFinancial press releaseDow jones newswires

Kintor Pharma Announces Oral Presentation at ASH 2022 Highlighting the Data from Novel Dual c-Myc/GSPT1 Degrader GT19715

/PRNewswire/ Kintor Pharmaceutical Limited ("KintorPharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and.

United statesNew orleansYuki nishidaKintor pharmaMichael andreeffDaudi burkittAmerican society of hematologyKintor pharmaceutical limited kintorpharmaUniversity of texas md anderson cancer centerKintor pharmaceutical limitedAmerican societyCancer centerYouzhi tongChief executive officerNovel dualCell death

Kintor Pharma Announces Oral Presentation at ASH 2022 Highlighting the Data from Novel Dual C-Myc-GSPT1 Degrader GT19715

DJ Kintor Pharma Announces Oral Presentation at ASH 2022 Highlighting the Data from Novel Dual C-Myc-GSPT1 Degrader GT19715 EQS Newswire / 10/11/2022 / 10:09 UTC+8 Kintor Pharma Announces Oral

United statesNew orleansYuki nishidaMichael andreeffKintor pharmaDaudi burkittAmerican society of hematologyUniversity of texas md anderson cancer centerFinancial pressKintor pharmaceutical limited pharmaPharma announces oral presentationNovel dualPharmaceutical limitedAmerican societyCancer centerYouzhi tong

Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US

/PRNewswire/ Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and.

Kintor pharmaChina national medical products administrationPrnewswire kintor pharmaceutical limited pharmaDrug administrationPharmaceutical limitedProteolysis targeting chimeraYouzhi tongChief executive officer

vimarsana © 2020. All Rights Reserved.